A carregar...
FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
BACKGROUND: Several progresses have been achieved for first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with Gem-NabP and FOLFIRINOX extensively used as standard first line regimens. However, the best second-line chemotherapy choice after progression is still not complete...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7585276/ https://ncbi.nlm.nih.gov/pubmed/33116881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S267393 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|